Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin

Thrombosis Research

Volumn 100, Issue 5, 2000, Pages 413-417

  Hansen, John Bjarne ^a   Naalsund, Trine ^a   Sandset, Per Morten ^b   Svensson, Birgit ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antithrombin; Coagulation activation; Heparin; Prothrombin fragment 1+2; TFPI

Indexed keywords

ANTITHROMBIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; CONTINUOUS INFUSION; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTITHROMBINS; BLOOD COAGULATION; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIPOPROTEINS; MALE;

EID: 0034519792     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00351-0     Document Type: Article

References (24)

1. Glycosaminoglycans and the regulation of blood coagulation
2. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
3. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
4. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
5. Enoxaparin - A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease
6. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
7. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
8. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): A possible mechanism for difference in therapeutic efficacy
9. An enzyme linked immunosorption assay for tissue factor pathway inhibitor
10. Heparin-induced decrease in circulating antithrombin-III
11. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide
12. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery
13. Multicentric evaluation of a new assay for prothrombin fragment F1 + 2 determination
14. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
15. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins
16. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model
17. The functional expression of tissue factor by fibroblasts and endothelial cells under flow conditions
18. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiological role for EPI as a natural anticoagulant
19. Total and free levels of tissue factor pathway inhibitor: A risk factor in patients with factor V Leiden?
20. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis
21. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
22. Reactivation of unstable angina after discontinuation of heparin
23. Enoxaparin versus unfractionated heparin after thrombolysis for acute myocardial infarction